NanoViricides extends employment terms for President Diwan and CFO Vyas
The company reported the executive agreement extensions in an 8-K with an earliest-event date of September 28, 2026, signed September 29, 2026.
SEC filing
Latest
4 stories
Tuesday, September 29
Thursday, July 30
NanoViricides closes $3.8 million offering, cuts ATM capacity to zero
The registered direct offering closed July 27, 2026, while a same-day amendment shows the company's at-the-market facility now caps eligible sales at zero.
SEC filing (3)
Friday, July 17
NanoViricides sets up at-the-market stock offering with D. Boral Capital
The company can now sell shares periodically through D. Boral Capital under a new sales agreement filed July 17, 2026.
SEC filing
Nanoviricides files $4 million at-the-market stock offering with D. Boral Capital
The clinical-stage antiviral company registered a prospectus supplement dated July 17, 2026 to sell up to $4,018,069 in common stock through an at-market sales agreement.
SEC filing